Valuation : Guided Therapeutics, Inc.

Market Cap 24.13M 20.79M 19.69M 17.85M 33.48M 2.31B 33.65M 234M 89.92M 1.17B 90.64M 88.65M 3.71B P/E 2024
-3x
P/E 2025 -12.7x
Enterprise Value 27.01M 23.27M 22.04M 19.97M 37.47M 2.58B 37.66M 262M 101M 1.31B 101M 99.21M 4.15B EV / Sales 2024
1,649x
EV / Sales 2025 64.4x
Free-Float
63.48%
Yield 2024 *
-
Yield 2025 -
10/09 Guided Therapeutics, Inc. and Türkiye Ministry of Health Reach Collaborative Agreement for Primary Screening Test for Cervical Cancer CI
14/08 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
15/07 Guided Therapeutics, Inc. Announces New Agreement With Yuanshuo Medical Instruments Corporation CI
17/06 Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA CI
16/05 Guided Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
31/03 Guided Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
31/03 Guided Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
18/12 Guided Therapeutics, Inc. Announces Preliminary Findings from Its FDA Pivotal Clinical Trial CI
12/12 Guided Therapeutics, Inc. Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor CI
20/11 Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation CI
14/11 Guided Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
19/08/25 Guided Therapeutics, Inc. Receives $70,000 from New Chinese Distribution Partner That Provides Products for 2 Million Annual Cervical Cancer Screenings CI
15/08/25 Guided Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
1 day+25.00%
1 week+25.00%
Current month+11.11%
1 month-13.79%
3 months+23.30%
6 months-13.79%
Current year-53.70%
1 week 0.18
Extreme 0.1818
0.25
1 month 0.18
Extreme 0.18
0.29
Current year 0.17
Extreme 0.17
0.54
1 year 0.15
Extreme 0.15
0.54
3 years 0.06
Extreme 0.064
0.54
5 years 0.06
Extreme 0.062
0.78
10 years 0.02
Extreme 0.0206
3,200
Manager TitleAgeSince
Chief Executive Officer 70 06/03/2023
Chief Tech/Sci/R&D Officer 70 02/12/2010
Director TitleAgeSince
Director/Board Member 70 01/12/2016
Director/Board Member 76 10/04/2006
Chairman 67 01/10/2013
Date Insider Type Main position Quantity % Market Cap. Importance
10/3/26 Free

Chairman

110,000 0.1316%
10/3/26 Others

Director

466,991 0.5586%
10/3/26 Free

Director

110,000 0.1316%
Change 5-day change 1-year change 3-year change Capi.($)
+25.00%+25.00%-10.55%+76.60% 24.13M
+1.10%-0.65%+24.10%+18.43% 225B
-0.19%-3.62%+2.55%-20.00% 141B
+2.41%+0.67%-19.02%+22.09% 130B
-0.28%-10.08%-58.81%-21.22% 62.29B
-2.77%-6.15%+8.15%+12.69% 48.63B
-0.49%-1.97%-20.35%-15.53% 49.39B
+2.66%-2.61%+15.94%+29.91% 41.42B
+1.67%-0.25%+35.01%+55.09% 40.12B
-0.60%-4.41%-20.52%+44.06% 31.23B
Average +2.86%-3.08%-4.35%+20.21% 76.97B
Weighted average by Cap. +0.52%-2.50%+0.60%+9.84%

Financials

2024 2025
Net sales 7K 6.03K 5.71K 5.18K 9.71K 669K 9.76K 67.83K 26.08K 340K 26.29K 25.71K 1.08M 767K 661K 626K 567K 1.06M 73.28M 1.07M 7.43M 2.86M 37.28M 2.88M 2.82M 118M
Net income -2.42M -2.08M -1.97M -1.79M -3.35M -231M -3.37M -23.42M -9.01M -117M -9.08M -8.88M -371M -3.2M -2.75M -2.61M -2.36M -4.43M -305M -4.46M -30.97M -11.91M -155M -12M -11.74M -491M
Net Debt 1.77M 1.53M 1.44M 1.31M 2.46M 169M 2.47M 17.16M 6.6M 86.08M 6.65M 6.51M 272M 2.88M 2.48M 2.35M 2.13M 3.99M 275M 4.01M 27.87M 10.72M 140M 10.8M 10.56M 442M
Logo Guided Therapeutics, Inc.
Guided Therapeutics, Inc. is a medical technology company. The Company is focused on developing medical devices that have the potential to improve healthcare. The Company’s primary focus is the sales and marketing of its LuViva Advanced Cervical Scan non-invasive cervical cancer detection device. The underlying technology of LuViva primarily relates to the use of biophotonics for the non-invasive detection of cancers. LuViva is designed to identify cervical cancers and precancers painlessly, non-invasively and at the point of care by scanning the cervix with light, then analyzing the reflected and fluorescent light. LuViva is designed to provide a less invasive and painless alternative to conventional tests for cervical cancer screening and detection. Additionally, LuViva is designed to improve patient well-being not only because it eliminates pain, but also because it is convenient to use and provides rapid results at the point of care.
Employees
3
Date Price Change Volume
09/09/26 USD 0.2500 +25.00% 45,439
08/09/26 USD 0.2000 0.00% 8,740
04/09/26 USD 0.2000 -15.79% 7,801
03/09/26 USD 0.2375 -5.00% 6,551
  1. Stock Market
  2. Stocks
  3. GTHP Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!